International Journal of Web of Multidisciplinary Studies
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
website: http://ijwos.com
Vol.02 No.12.
OPEN ACCESS
E-ISSN : 3049-2424
DOI: https://doi.org/10.71366/ijwos
IJWOS International Journal of Web of Multidisciplinary Studies

Technology Transfer Steps from R&D to Production in a Pharmaceutical Company

Dhiraj Vilas Mistari[1], Sanjana Devidas Tandekar[2], Mubeen Ahmad[3]
[1,2] *Last Year B pharmacy student, Aditya Institute of pharmacy, Chalisgaon*
[3] *Assistant Professor, Aditya Institute of pharmacy Chalisgaon, India.*

Article Info

Article History:

Published:24 Dec 2025

Publication Issue:
Volume 2, Issue 12
December-2025

Page Number:
477-497

Corresponding Author:
Dhiraj Vilas Mistari

Abstract:

Technology transfer (TT) from R&D to commercial manufacturing is a pivotal process in the pharmaceutical industry, enabling the translation of laboratory- scale innovations into scalable, compliant, and economically viable production. This review provides a structured overview of the key steps in this transition, highlighting critical success factors and potential challenges. The main phases include: (1) Knowledge and Data Transfer, where formulation data, process design, and analytical methods are compiled into a technology transfer dossier (TTD) ; (2) Risk Assessment and Process Characterization, with tools such as Failure Mode and Effects Analysis (FMEA) to identify critical quality attributes (CQAs) and critical process parameters (CPPs) (3) Scale-up Strategy, involving lab-to-pilot, pilotto-commercial scale batches and the development of scale-down models ; (4) Analytical Method Transfer, validation, and verification in the new production environment ; (5) Process Validation and Continued Process Verification, including process qualification batches and design space verification during commercialization ; (6) Documentation and Training, ensuring all operating procedures (SOPs), control strategies, and personnel expertise are aligned between R&D and manufacturing ; and (7) Handover & Lifecycle Management, with feedback loops for continuous improvement and regulatory compliance . Critical enablers include cross-functional governance, strong project management, and a science- and risk-based Quality by Design (QbD) framework. Despite its structured nature, TT faces various barriers such as equipment incompatibility, communication gaps, and variability in raw materials. Addressing these requires a proactive, well-documented, and collaborative approach. This review concludes that a disciplined, knowledge-driven, and risk- managed technology transfer not only ensures operational continuity anregulatory readiness, but also helps maintain product quality and robustness across scale .

Keywords: Technology transfer

1. Introduction

Technology transfer (TT) in the pharmaceutical industry is the structured process by which knowledge, methods, and controls developed during research and development (R&D) are conveyed to manufacturing operations so that a drug product can be produced reliably, reproducibly, and at commercial scale. This transition is not merely a hand-off of a laboratory recipe; rather, it is a complex, cross-functional undertaking involving formulation scientists, process engineers, quality assurance (QA), regulatory affairs, analytical development, and manufacturing teams.

A well-executed technology transfer underpins critical business objectives: ensuring consistent product quality, reducing risk of manufacturing failures, accelerating time to market, and establishing a robust control strategy for long- term production. The process is anchored in quality-by-design (QbD) principles, where early identification of critical quality attributes (CQAs) and critical process parameters (CPPs) helps define a design space and control strategy that promote process robustness.

One major challenge in technology transfer is the difference between the development environment and the manufacturing environment. Equipment scale, raw material variability, and environmental conditions often change, causing process behavior to shift. In biologics, for example, upstream processing must often be re-optimized to account for scale-dependent parameters such as pH, dissolved oxygen, or mixing dynamics. Risk assessment, typically using tools such as Failure Mode and Effects Analysis (FMEA), plays a central role in identifying potential scale-up risks and guiding mitigation strategies. Moreover, a successful technology transfer necessitates comprehensive documentation.

The development team compiles a Technology Transfer Dossier (TTD) that includes the master formula card, process flow diagrams, specifications (in-

process and final), analytical methods, validation protocols, and stability data. Regulatory expectations (e.g., ICH Q10, which outlines pharmaceutical quality systems) place TT at the heart of process qualification, control strategy, and continual improvement.

Given the high regulatory, financial, and operational stakes, technology transfer must be executed with rigor and systematic planning. Poorly managed transfers can lead to batch failures, regulatory non-compliance, and supply disruptions. Conversely, effective transfer supports scalability, reproducibility, and quality, laying the foundation for robust commercial production. In this review, we examine the key stages of technology transfer—from process development, risk assessment, and documentation, through scale-up, qualification, and routine commercial manufacturing—and discuss best practices, challenges, and regulatory considerations.

Technology transfer (TT) is a critical process in pharmaceutical development, enabling the seamless transition of a drug candidate from research and development (R&D) into full-scale commercial manufacturing. It involves the systematic transfer of product knowled manufacturing processes, analytical methods, quality standards, and regulatory expectations from the sending unit (typically R&D or pilot-scale facilities) to the receiving unit (often large-scale manufacturing sites). The purpose of technology transfer is to ensure that the product can be consistently manufactured at commercial scale while maintaining predefined quality, safety, and efficacy criteria.

3) Importance of Technology Transfer in the Pharmaceutical Industry : -

Technology transfer (TT) is a critical component in the pharmaceutical product lifecycle, enabling the transition of a drug product from research and development (R&D) to full-scale commercial production. A successful TT ensures that the manufacturing process is robust, reproducible, compliant, and capable of consistently delivering a product that meets predefined quality standards. The major reasons for its importance are highlighted below. 1. Ensures Consistent Product Quality and Safety TT enables the transfer of all product and process knowledge—including Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs)—from R&D to manufacturing. This ensures that the final product maintains the same quality, safety, and efficacy demonstrated during development.

1 . Ensures Consistent Product Quality and Safety -

TT enables the transfer of all product and process knowledge—including Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs)—from R&D to manufacturing. This ensures that the final product maintains the same quality, safety, and efficacy demonstrated during development.

2. Supports Regulatory Compliance -

Regulatory agencies require documented evidence of knowledge transfer and process understanding. Proper TT ensures compliance with GMP, ICH Q8–Q11, and process validation expectations.

3. Facilitates Smooth Scale-Up and Commercial Manufacturing - Technology transfer bridges the gap between laboratory-scale processes and full- scale commercial production. It allows the manufacturer to adjust and optimize process parameters for larger batch sizes while maintaining product quality.

4. Enhances Process Robustness and Reduces Manufacturing Risks –

TT includes risk assessments (such as FMEA) and pilot studies that help identify and mitigate potential failure points. This minimizes:

- Batch failures
- Deviations
- Out-of-specification (OOS) results
- Production delays

5. Enables Knowledge Preservation and Transfer Across Sites –

TT captures both explicit knowledge (documents, protocols, specifications) and tacit knowledge (practical experience, troubleshooting insights). This supports:

- Training of production teams

- Transfer between multiple manufacturing sites
- Continuity when personnel change

6. Improves Cost Efficiency and Operational Performance –

Effective TT reduces:

- Process variability
- Material wastage
- Rework and batch rejection
- Costly delays during scale-up

It also improves capacity utilization and overall operational efficiency.

7. Supports Global Manufacturing and Outsourcing –

With many pharmaceutical companies outsourcing manufacturing to Contract Manufacturing Organizations (CMOs), TT ensures smooth and compliant transfer of processes to third-party sites.

8. Critical for Lifecycle Management and Continuous Improvement –

Throughout the drug's lifecycle, changes such as:

New dosage strengths ,New manufacturing sites ,Equipment upgrades

4) Classification of Technology Transfer in the Pharmaceutical Industry -

technology transfer (TT) in the pharmaceutical sector can be classified in several ways based on direction of transfer, level of technology maturity, purpose, and organizational structure. These classifications help define the strategic approach and provide clarity in managing transfer processes between R&D and manufacturing.

Based on the Direction of Transfer –

1.1) Vertical Technology Transfer

Also known as internal or intra-organizational TT, this is the most common type in pharmaceuticals. Transfer of technology from R&D → Pilot Plant → Commercial Production. Ensures product development progresses through structured stages. Includes scale-up, process validation, and analytical method transfer. Examples: Lab-scale development to manufacturing; transferring analytical methods from development lab to QC.

1.1.Horizontal Technology Transfer

Transfer of technology between two similar-level entities, often between different manufacturing sites.

Applied when a company wants to produce the same product at multiple locations.

Common during global expansion or supply chain diversification.

Examples : - Commercial site in Country A transferring the same process to another plant in Country B.

1.2) Diagonal Technology Transfer

Combination of vertical and horizontal transfer.

R&D → Manufacturing Site 1 → Manufacturing Site 2.

Often used when scaling up and then distributing technology internationally. Examples: Technology first optimized at a pilot plant and then transferred to a contract manufacturing organization (CMO).

2. Based on Type of Technology Being Transferred 2.1.Manufacturing Process Technology Transfer

Transfer of formulation, processing steps, CPPs, batch manufacturing records, equipment settings.

Includes upstream and downstream processing for biologics.

2.2. Analytical Method Transfer Includes analytical procedures, validation protocols, acceptance criteria, and testing methods. Ensures QC laboratories can reproduce accurate results

2.3. Knowledge / Documentation Transfer

Transfer of development reports, risk assessments, stability data, process optimization history. Critical for regulatory compliance and training.

2.4. Equipment and Facility Transfer

Transfer of specifications, equipment design qualification requirements (IQ/OQ/PQ), and facility.Layout . Ensures alignment with GMP expectations

3. Based on the Source and Recipient Relationship 3.1.Internal Technology Transfer

- Occurs within the same organization.
- Most common in pharmaceutical R&D-to-production workflows.
- Supports continuous product lifecycle management.

3.2.External Technology Transfer

Transfer between different organizations.

Often involves CMOs, CROs, licensing partners, or collaborators.

Requires detailed technology transfer agreements and confidentiality protections.

4. Based on Purpose of Transfer 4.1.Developmental Transfer

Transfer performed during product development before commercialization.

Lab → Pilot → Scale-up.

Helps optimize processes and define CPPs and CQAs.

4.2 Manufacturing Transfer

Transfer for routine commercial production after regulatory approval.

Used for capacity expansion, cost reduction, or regional production.

4.2.Post-Approval Transfer

Transfer after regulatory approval due to:

- Site change
- Equipment change
- Lifecycle management needs
- Outsourcing decisions

Requires regulatory filings (e.g., SUPAC, variation submission).

5. Based on Level of Complexity

5.1. Simple Technology Transfer

Involves straightforward processes (e.g., simple solid oral dosage forms). Minimal change in equipment or process setup.

5.2. Complex Technology Transfer

Involves advanced technologies or biologics.

Requires extensive risk assessments, modeling, and multi-stage validation. Examples:

1. Nanoparticle-based medicines
2. Cell and gene therapy production
3. Monoclonal antibody (mAb)
4. processes Sterile or aseptic formulations

5) Methods of Technology Transfer in the Pharmaceutical Industry

: -

Technology transfer (TT) involves systematic processes that allow the successful movement of knowledge, skills, technologies, and manufacturing processes from Research & Development (R&D) to Pilot Plant and then to Commercial Production. Various methods of technology transfer are employed depending on the complexity of the product, regulatory requirements, and manufacturing capabilities. The following methods are widely recognized in pharmaceutical practice and regulatory guidance.

1. Documentation-Based Technology

Transfer This is the most fundamental and universally used method.

It involves transferring all essential documents from the donor (R&D) to the receiver (Production/QC/QC labs).

Key components transferred:

- Master Formula Record (MFR)
- Batch Manufacturing Record (BMR)
- Standard Operating Procedures (SOPs)
- Equipment qualification documents (IQ/OQ/PQ)
- Process validation protocols
- Analytical method validation documents
- Development reports and historical data

This method ensures complete knowledge capture and regulatory compliance.

Demonstration-Based (On-Site) Technology Transfer

Also called hands-on transfer, it involves physical demonstration of processes and methods by R&D experts at the manufacturing site.

Includes:

- On-site trial batches
- Demonstration of critical steps
- Training in equipment operation
- Supervised process runs
- Real-time troubleshooting

This method is crucial for complex products (e.g., biologics, sterile injectables) where practical learning is essential.

2. Training-Based Technology Transfer

This method focuses on transferring skills and competencies. Training types:

- GMP training Equipment handling and maintenance
- Analytical method training
- Safety and aseptic technique training
- Process-specific training modules

Training may be delivered through:

- Workshops
- Seminars
- Hands-on laboratory sessions
- E-learning modules
- Shadowing experienced personnel

3. Pilot-Scale / Trial Batch–Based Technology Transfer

Before commercial-scale manufacturing, pilot-scale batches are executed to verify scalability.

Activities include:

- Engineering batches
- Scale-up trials
- Process parameter optimization
- Risk assessment (FMEA)
- Equipment capability evaluation
- This method helps identify potential issues early and ensures a smooth transition to full production.

4. Analytical Method Transfer

This method ensures that the receiving Quality Control (QC) laboratory can perform testing reliably.

It includes:

- Full method validation
- Method verification
- Co-validation between donor and receiver
- Comparative testing of samples
- Documentation of acceptance criteria

This is mandatory for regulatory compliance (FDA, ICH Q2(R1)).

5. Digital / Electronic Technology

Transfer With digitalization, many companies now use electronic systems for TT. Tools include:

- Electronic transfer of documents
- Quality Management Systems (QMS)
- Pharmaceutical ERP and MES systems
- Electronic batch records (eBMR)
- Digital dashboards for CPP/CQA monitoring
- Knowledge management systems

6. Collaborative / Cross-Functional Technology Transfer

This method involves direct collaboration between cross-functional teams: Teams include:

- R&D
- Production Quality Assurance (QA)
- Quality Control (QC)
- Engineering
- Regulatory Affairs

Regular meetings, joint decision-making, and technical reviews ensure a smooth and aligned TT process.

7. Outsourcing-Based Technology Transfer (External TT)

Used when transferring technology to a Contract Manufacturing Organization (CMO) or another company.

Required steps:

- Technical transfer agreements
- Confidentiality agreements (NDA)
- On-site audits of the receiving facility
- Joint process development
- Shared validation responsibilities

This method demands strict regulatory and documentation control.

6) Factors influencing of technology transfer in pharmaceutical industries : -

1. Investment in R&D.
2. Establishing the link between production and research.
3. Data development within the field of technology transfer methods.

4. Organizational and Informational infrastructures.
5. Awareness of basic and necessary factors need for technology transfer.
6. Consideration of existing and old technologies.
7. Good business and manufacturing practices. The company's success is primarily the result of its adopt of good business and manufacturing practices, particularly in the area of product identification and formulation technology.
8. Potential for competitive pricing: Balance cost to remain competitive by having higher private sector prices and very low public sector prices
9. Strategic planning: Create an enabling environment for vertical integration, with the prospect for higher capacity utilization and eventual lowering of production cost.
10. Strong economy and environment: For Technology transfer to be successful their needs to be a supportive business and scientific environment in the recipient country, and that environment should include skilled workers, Economic and political stability, supportive regulatory environment, market size, and potential.
11. Transparent rent and efficient regulations: Pharmaceuticals is necessarily a highly regulated industry, the regulatory function must be efficient and transparent for technology transfer to be economically viable.
12. Opportunities for contingency supply: Multinational pharmaceutical companies are inclined to transfer technology to local manufactures with the potential to receive when they foresee an inability to meet time scale and volume demand from large procurers.

7) ORGANIZATION OF TECHNOLOGY TRANSFER : -

Since a team concept is always the best approach to accomplishing a successful technology transfer project.

The core technology transfer team should be commissioned immediately following the decision of executive management to pursue the drug candidate to commercialization. Typical technology transfer core team will Likely be comprised f individuals representative of different segments of the business.

1. Project Manager- For overall responsibility, coordination, and progress communication to management. His or her role may be enhanced as necessary by additional staff & responsibility & authority delegated as appropriate.
2. Regulatory Affairs- For coordination of the appropriate regulatory filings, advice on approval timing, the content of the filing documentation & response to regulatory inquiries.
3. Engineering- To coordinate associated capital projects & direct & control construction, equipment

Acquisition, installation & qualification.

5. Material management- To include those units responsible for pure chasing. Strategic planning, resource allocation & supply chain activities. This member (or members) will analyze & recommend the most favorable manufacturing strategy in consideration of internal capability, business partnership & tax advantages for the corporation.
6. Manufacturing operations-
   To represent the originating site and receiving location production activities.

8) Key Steps of Technology Transfer (R&D → Production)

1. Technology Package Preparation

R&D prepares a comprehensive Technology Transfer Dossier. Includes:

- Product composition and Quality Target Product Profile (QTPP)
- Critical Quality Attributes (CQAs)
- Process development history
- Analytical methods and validation data
- Raw material specifications
- Clinical and stability data

2. Risk Assessment and GAP Analysis

Identification of: Critical Process Parameters (CPPs) , Critical Material Attributes (CMAs) , GAP analysis between R&D small-scale processes and commercial equipment capabilities.

Risk analysis tools used:

FMEA, Ishikawa diagram, DOE analysis

3. Pilot-Scale (Scale-Up) Studies : - The R&D process is transferred to a pilot plant for intermediate-scale manufacturing.

Purpose:

Evaluate scalability of mixing, granulation, drying, coating, filtration, bioreactors etc. Optimize process conditions.

Identify scale-dependent challenges (heat transfer, mass transfer, equipment geometry).

4. Process Optimization and Parameter Confirmation Fine-tuning of CPPs, control strategies, and batch protocols. Equipment qualifications (IQ/OQ/PQ) at the receiving site.

5. Analytical Method Transfer Analytical methods transferred from R&D QC lab to Manufacturing/QC lab. Includes: Method verification or revalidation Training of QC analysts Inter-lab comparison and concordance studies

HOW TECHNOLOGY TRANSFER IS HELPFUL?:

Academics and research institutes engaged in technology transfer for a variety of reasons such as,

1. Lack of Manufacturing Capacity: The developer of the technology could solely have to produce instrumentation that appropriates for lab and small-scale operations and should partner with another organization to try to do massive scale manufacturing.
2. Lack of Resources to Launch Product Commercially: The original inventor of technology may only have resources to conduct early stages research and phase I and II clinical trials.
3. Lack of Marketing Distribution and Distribution Capability: The developer of the technology could have absolutely developed technology and even have obtained regulative approvals and product registration, but it may not have the marketing and distribution channels.
4. Exploitation in a different field of application: Each partner may have only half of the solution ie. The developer of the technology might be capable of exploiting the technology itself in the field of diagnostic applications and may grant exploitation right to commercial partner for the exploitation of therapeutics application.
5. Forming alliances with partners: That can progress the development of the technology to take it to market.
6. Forming alliances with partners with manufacturing capability.
7. Local economic development. 8. The attraction of corporate research support,

9) STEPS INVOLVED IN THE TECHNOLOGY TRANSFER PROCESS:

During the development of a formulation, it is important to understand the procedure of operations used, critical and non-critical parameters of each operation, production environment, equipment, and excipient availability should be taken into account during the early phases of development of formulation.

Chart 1 . Quality Control & Assurance Steps

(A) Development of technology by R&D. (Research Phase) –

(a) Design of procedure and selection of excipients by R&D-Selection of materials and design of procedures is developed by R&D based on innovator product characteristics.

(b) Identification of specifications and quality by R&D-Quality of product should meet the specifications of an innovator product.

(B) Technology transfer from R&D to production (Development Phase) –

R&D provides technology transfer dossier (TTD) document to product development laboratory, which contains all information of formulation and drug product as follows –

(a) Master Formula Card (MFC) Includes product name along with its strength, generic name. MFC number. Page number, effective date, shelf life, and market.

(b) Master Packing Card Gives information about packaging type, the material used for packaging, stability profile, and shelf life of packaging.

© Master Formula Describes formulation order and manufacturing instructions. (Process order and environment conditions.)

(c) Specifications and Standard Test Procedures (STP) Helps to know active ingredients and excipients profile, in-process parameters, product release specifications, and finished product details.

© Optimization and Production. (Production Phase) –

(a) Validation Studies Production is implemented after validation studies that can verify that process can stabilize the product based on transferred manufacturing formula. The manufacturing department accepting technology is responsible for validation and the R&D department transferring technology should take responsibility for validation such as performance qualification, cleaning, and process validation.

(b) Scale-up for production Involves the transfer of technology during small-scale development of the product and processes. It is essential to consider the production environment and system during the development of a process. Operators should concentrate on keeping their segment of the production process running smoothly.

D) Technology Transfer Documentation –



Generally interpreted as document indicating contents of technology transfer for transferring and transferred parties. Each step from R&D to production should be documented, task assignments and responsibilities should be clarified, and acceptance criteria for completion of technology transfer concerning individual technology to be transferred. The Quality Assurance department has to check and approve the documentation for all processes of technology transfer.

(a) Development Report-The R&D report is a file of technical development, and the R&D department is in charge of its documentation. This report is an important file to indicate the rationale for the quality design of drug substances and its specifications and test methods. The development report is not a prerequisite for the application for approval; it can be used at the pre-approval and inspection as a valid document for the quality design of the new drug. The development report contains –

E) Exhibit –

After taking scale-up batches of the product, manufacturing of exhibit batches takes place. In the case of an exhibit, batch sizes are increased along with equipment and their processes. This is done for filling purposes in regulatory agencies.

TECHNOLOGY TRANSFER FLOW CHART:

10) Contents of technology transfer

1 Proper Research By proper research we mean firstly that in which the result is reproducible and issues such as scale-up, stability, etc, and other practices now have been addressed, also that in which problems. Were taken up in first place.

1. Proper work- This refers to institutional and guidelines regarding IP Protection licensing modalities etc. which must be in place beforehand. In the absence of these, the decision gets delayed, lack of fairness in decision e.g. case of X institute, which came up with good technology but since no guidance was there, kept running around for two years and then gave up.
2. Pricing most difficult and critical area of Transfer of technology. Too high a price can put off buyers, leaving the technology unsold. Too price a result in revenue loss. There are two models regarding pricing Price charged for technology should depend upon market force te. Impact of the technology. Irrespective of the amount spent on developing it. The price charged should include all expenses involved in developing it.
3. Publicity It is important to identify and then approach the buyer i.e. adopt targeted Publicity and not blanket publicity. Specific journal, website, letters to the manufacturer, personal selective visit, etc. are some common approach which helps in locating a buyer.
4. People's Acceptance – It is no use trying to develop a technology which people will not accept e.g. due to religious reasons/social concern etc.



genetically modified food, irradiated vegetables processed beef in India, the improved capsule made of non-vegetarian material,

- BARRIERS OF TT

5. 4. Lack of market share: Local producers face significant challenges in meeting international quality standards and capturing a critical market share. Greater market share would increase profitability.

6. B. Cost of pre-qualification: There is a benefit in meeting international standards since it opens up the opportunity for trading across the entire world. 11.

C. Labor issues: The pharmaceutical sector demands relatively skilled labor. High labor turns over and absenteeism owing to unattractive conditions of service is a negative contributor.

7. D. Unsuccessful or incomplete Process Validation.

8. E. High rates of batch rejections, excessive labor requirements, increased cost of a product, etc.

11) TECHNOLOGY TRANSFER TEAM MEMBERS AND THEIR RESPONSIBILITIES : -

Technology Transfer team Members	**Responsibilites**
Process Technologist	1. Serves as the central focus for transfer activities. 2. Collates and documents information from the donor source. 3. Performs an initial assessment of the transferred project for feasibility, compatibility with site capabilities, and determines resource needs.
QA Officer	1. Reviews documentation to ensure compliance with the Marketing Authorization (MA). 2. Reviews analytical strategies with QC to assess capability and identify any instrumentation or training requirements. 3. Initiates the conversion of donor-site documentation into local systems or formats. 4. Initiates or confirms regulatory needs (e.g., an amendment, manufacturing notification, or variation to the MA) if a method change is required.

Engineering Officer	1. Reviews instrumentation requirements together with a Production representative. 2. Initiates required engineering modifications, changes, or purchase of parts/equipment. 3. Reviews and prescribes maintenance and calibration for testing rigs used for tests of aggressive, temperature-sensitive, or otherwise critical materials, and updates requirements accordingly.

Technology Transfer team Members	**Responsibilites**
QC Officer	1. Reviews analytical requirements. 2. Assesses availability and suitability of instruments. 3. Responsible for analytical transfer for drug substance and drug product.

12) Technology Transfer Documentation:

A technology transfer summary report, which should present an outline of the extent of transfer, should be prepared and described by documenting the data in every phase of transmission that can be regarded successful. Potential deviation should he recorded and appropriate decisions made, sorting them before/during the procedure is recommended. From the beginning to the end of the procedure, data is recorded , Following are the documents .

7. Critical quality attributes
8. Critical process parameters.
9. Standard operating procedure (SOP)
10. Stability data of data of Lab scale validation
11. Batches (at least 6 months real time study)
12. Lab Batch Manufacturing Record (BMR)
13. Batch packaging record.
14. Pilot Batch Manufacturing Record (BMR
15. Drag Master File (DMF).
16. Analysis of excipients
17. Raw Material Certificate of analysis

18. Analytical method validation
19. Cleaning Validation report
20. Process validation report.
21. Standard test procedure.
22. Facilities & Equipment validation report
23. Specifications Change control form.
24. Complaints
25. Deviation reports
26. Technology Transfer summary report,
27. Training Documentation
28. Product Specification (Product Specification File

13. CONCLUSION

Appropriate technology transfer is a critical component in ensuring that the quality of product design, development, and manufacturing continues to advance in a controlled and scientifically justified manner. It plays a central role in establishing a robust and reliable manufacturing process that consistently delivers products of high quality, safety, and efficacy. Effective technology transfer supports the continuity of product knowledge

throughout the product lifecycle and ensures that all essential technical, analytical, and operational information is accurately communicated from the sending unit to the receiving unit.

Technology transfer is not limited to a series of one-time activities or simple document handovers. Instead, it represents a comprehensive, structured, and ongoing exchange of information, expertise, and experience between both parties. This continuous interaction helps ensure that the receiving unit fully understands the critical aspects of the process, including raw materials, in-process controls, equipment configurations, analytical requirements, and the risks associated with each step. The quality of the transfer directly influences the reliability of commercial-scale manufacturing and long-term product performance.

A successful technology transfer involves clarity, transparency, and collaboration across multidisciplinary teams, including manufacturing, quality control, quality assurance, engineering, regulatory affairs, and development units. It requires detailed planning, risk assessment, qualification of equipment, verification of analytical methods, and alignment on critical quality attributes (CQAs) and critical process parameters (CPPs). Thorough documentation, including technology-transfer protocols, reports, change controls, and regulatory filings,

ensures that the process remains compliant with internal quality standards and external regulatory expectations.

Technology transfer can be considered successful only when the receiving unit demonstrates the capability to routinely and reproducibly manufacture the product or perform the analytical method within predefined limits. This performance must be consistent with the specifications, acceptance criteria, and regulatory commitments agreed upon by the sending unit, receiving unit, and, where applicable, the development unit. Furthermore, the process should remain robust under normal operating conditions, adaptable to scale-up, and capable of withstanding routine manufacturing variability without compromising product quality.

In addition, effective technology transfer contributes to operational efficiency by reducing the likelihood of process deviations, minimizing manufacturing failures, supporting faster troubleshooting, and enabling smoother regulatory inspections. It strengthens the organization's overall technical capability, enhances readiness for commercial production, and creates a strong foundation for future process optimization and continuous improvement initiatives. Ultimately, a well-executed technology transfer ensures not only the successful transition of processes and knowledge but also the long-term sustainability, reliability, and competitiveness of the manufacturing operation.

References

1. ICH Q8 (R2), Pharmaceutical Development, International Conference on Harmonisation (ICH), 2009.
2. FDA: Process Validation: General Principles and Practices, 2011.
3. International Society for Pharmaceutical Engineering (ISPE). Good Practice Guide: Technology Transfer, 3rd Edition, 2018.
4. ICH Q10: Pharmaceutical Quality Systems, 2008.
5. Waghmare Y.S., Mahaparale S. The Importance of Technology Transfer in Pharmaceutical Industry – A Review. World Journal of Pharmaceutical Research, 2017; 6(9): 310-329.
6. Manikandan V., Kathiresan K. Technology Transfer from R&D to Production in Pharmaceutical Industry. International Research Journal of Pharmacy, 2021; 12(10): 13- 16.
7. Chatterjee B., Mitchell M. A Framework for Technology Transfer to Satisfy the Requirements of Process Validation Guidance. Pharma Manufacturing Journal, 2012.
8. ICH Q9: Quality Risk Management, 2005.
9. ISPE: Technology Transfer Guide, 2018.
10. Mahajan S.S., Zite R.M. Technology Transfer in Pharmaceutical Industry: An Overview. WJPR, 2021; 10(7): 121-127.
11. Pawar S.A., Pawar P.A. Technology Transfer in Pharmaceutical Industry: A
12. Comprehensive Review. IJMPBS, 2023.
13. FDA: Pharmaceutical CGMPs for the 21st Century A Risk-Based Approach
14. Haigney S. Evaluating the Tech Transfer Process. Pharmaceutical Technology, 2019.
15. Dr. Ramnathan K. An Overview of Technology Transfer & Technology Models.

16. Reddy, N.M. & Zhao, L. International Technology Transfer: A Review, research policy, 19(4): 285-307.
17. Van wyk, R.J. “Management of Technology: New frameworks” Technvation,
18. 7: 341-351 (1988)
19. Gupta, Surbhi Saini, Seema. Technology Transfer in Pharmaceutical Industry An Overview. International Pharmaceutica Science. 2(3): 1-6 (2012)
20. Dr. Ramanathan K. The Polytropic components of Manufacturing Technology, Technological Forecasting & Social change, 46: 221-258 (1994)
21. Souder, W.E. Nashar, A.S. Padmanathan, V. A Guide to The Best Technology Transfer Practice, Journal of Technology Transfer, 15: 1-2 (1990)
22. Bradley. S.R. Hayter, C.S. Link. A.N. Models & Methods of University Technology Transfer, Department of Economics Working Paper Series. The University of North America Grecensboro, June-2013, pg no- 6-9
23. Le Trong Vu, P. Eng. Technology Transfer Challenges in Pharmaceutical Indusry, Joint CVG/Therapeutic Products Directorate International Convention & Exhibition, Toronto, Canada, Octo. 5-6. 2006 pg no-1-
24. Guidelines of Technology Transfer.
25. Patil, R.P. Technology Transfer in Pharmaceutical Industry: objectives, Issues & Policy Approaches, Int J Pharm. Res. Dev. 2(10): 43-48 (2010)
26. Ortega, A. J. Arce, N.A. Sequeda, F. Gribenchenko, I. Management of Innovation & Technology Transfer Process Between University & Industry. The Master Res Cent case. 2: 7-8 (2009)
27. George, P. Millili, Senior Director Pharmaceutical Commercialization Development, Scale up & Technology Transfer as a Part of Pharmaceutical Quality System pg no-1-7.